558/12612082/0512

Directions for Use

B. Braun Melsungen AG · 34209 Melsungen, Germany

50 % w/v Glucose Injection B. P.

Composition
100 ml of solution contain

Active substance:
Glucose monohydrate 55.0 g
(equivalent to anhydrous glucose, 50.0 g)

Excipients:
Water for injections

Pharmaceutical form
Concentrate for solution for infusion

Energy	835 kJ/100 ml ≙ 200 kcal/100 ml
Theoretical osmolarity	2770 mOsm/l
Acidity (titration to pH 7.4)	< 1.5 mmol/l
pH	3.5 – 5.5

Pharmaco-therapeutic group
Solution for parenteral nutrition - carbohydrates

Indications
Therapy of hypoglycaemia.

Contraindications
- Hyperglycaemia
- Hypokalaemia
- Acidosis.

Special warnings and precautions for use
Caution should be exercised in patients with increased serum osmolarity.
Blood glucose concentrations should be monitored, depending on metabolic conditions and administered dose.
Clinical monitoring should include serum electrolyte concentrations – in particular potassium – and the acid-base balance.
Glucose solutions should not be administered through the same infusion equipment, simultaneously with, before, or after administration of blood, because of the possibility of pseudo-agglutination.

Interactions
Because of its acid pH, 50 % w/v Glucose Injection B. P. may be incompatible with other medicaments.

Pregnancy and lactation
For glucose non data are available regarding its safety of use in pregnant or lactating women. Animal studies are insufficient with respect to reproductive toxicity.
In view of the well-known properties of glucose, no damaging effects on pregnant women, the embryo, fetus or suckling infant are to be expected from doses corresponding to the actual container sizes.

Effects on Ability to Drive and Use Machines
50 % w/v Glucose Injection B. P. has no influence on the ability to drive and use machines.

Dosage
The dosage is adjusted according to individual requirements or the actual blood glucose concentration.
In the critically ill, the administration rate should not exceed 6 mg of glucose per kg body weight per minute. Only exceptionally the administration rate may be up to 9 mg of glucose per kg body weight per minute.

Duration of use
50 % w/v Glucose Injection B. P. can be administered as long as medically indicated.

Method of administration
Intravenous use. Only to be used diluted as additive to intravenous infusions in order to avoid vein irritation.

Overdose
Overdose may cause hyperglycaemia, glucosuria, serum hyperosmolarity, possibly leading to hyperosmotic and hyperglycaemic coma, further hyperhydration and electrolyte disorders.
The primary therapy is dose reduction. Disorders of the glucose metabolism and of the electrolyte balance can be corrected by administration of insulin and appropriate supplementation of electrolytes.

Undesirable effects
If the product is used in accordance with the directions given, the occurrence of side effects is not to be expected.

B BRAUN

Schwarz
148x210 mm
558/12612082/0512
Lätus: 1637
Sri Lanka

558/12612082/0512

Note:
Patients are advised to inform their doctor or pharmacist of any adverse effect they notice in connection with the administration of this medicinal product.

Expiry date
The product must not be used beyond the expiry date stated on the labelling.

Instructions for storage / use / handling
Keep this medicine out of the reach and sight of children
Do not store above 25 °C.
The product is supplied in containers for single use only.
Remaining contents must not be stored for later use.
Only to be used if solution is clear and the container does not show visible signs of damage.

Shelf life after dilution:
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 ° C, unless dilution has taken place in controlled and validated aseptic conditions.

Date of last revision: 04.2010

B|BRAUN

B. Braun Melsungen AG
34209 Melsungen
Germany

Schwarz
148x210 mm
558/12612082/0512
Lätus: 1637
Sri Lanka